Literature DB >> 22997020

Sonographic hepatorenal ratio: a noninvasive method to diagnose nonalcoholic steatosis.

Valéria Ferreira de Almeida E Borges1, Angélica L D Diniz, Helma P Cotrim, Haroldo L O G Rocha, Nestor Barbosa Andrade.   

Abstract

PURPOSE: To evaluate the accuracy of the sonographic hepatorenal ratio (HRR) in the diagnosis and grading of nonalcoholic steatosis, using biopsy as the reference.
METHODS: Ultrasound (US) and liver biopsy were performed in 42 patients with nonalcoholic fatty liver disease. Forty healthy volunteers without steatosis at US and without risk factors for nonalcoholic fatty liver disease were also studied. The HRR was obtained by dividing the mean brightness level of region-of-interest pixels in hepatic parenchyma by that in renal parenchyma. Needle biopsy samples (hematoxylin-eosin stained) were classified as mild (5-33% fatty infiltration), moderate (>33-66%), or severe (>66%) steatosis. Spearman coefficient was used to evaluate the correlation between HRR and steatosis grade, analysis of variance for differences between subgroups, and receiver operating characteristic curve analysis for sensitivity and specificity.
RESULTS: Significant correlation was found between HRR and histologic steatosis (r = 0.80, p < 0.01). The HRR cutoff for predicting steatosis was ≥1.24 (sensitivity, 92.7%; specificity, 92.5%). The mean ± SD HRRs in controls and steatosis subgroups were control 1.09 ± 0.13, mild 1.46 ± 0.24, moderate 1.52 ± 0.27, severe 2.04 ± 0.3 and were significantly different from each other except between mild and moderate steatosis subgroups.
CONCLUSIONS: The HRR is a noninvasive, objective, and simple method that could be used to diagnose and grade hepatic steatosis.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22997020     DOI: 10.1002/jcu.21994

Source DB:  PubMed          Journal:  J Clin Ultrasound        ISSN: 0091-2751            Impact factor:   0.910


  15 in total

Review 1.  Non-invasive diagnosis of hepatic steatosis.

Authors:  Christiane Stern; Laurent Castera
Journal:  Hepatol Int       Date:  2016-10-25       Impact factor: 6.047

2.  Ultrasound hepatic/renal ratio and hepatic attenuation rate for quantifying liver fat content.

Authors:  Bo Zhang; Fang Ding; Tian Chen; Liang-Hua Xia; Juan Qian; Guo-Yi Lv
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

Review 3.  Radiologic evaluation of nonalcoholic fatty liver disease.

Authors:  Seung Soo Lee; Seong Ho Park
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 4.  The Global Nonalcoholic Fatty Liver Disease Epidemic: What a Radiologist Needs to Know.

Authors:  Keith Pereira; Jason Salsamendi; Javier Casillas
Journal:  J Clin Imaging Sci       Date:  2015-05-29

5.  Ultrasound in chronic liver disease.

Authors:  J F Gerstenmaier; R N Gibson
Journal:  Insights Imaging       Date:  2014-05-24

Review 6.  Nonalcoholic fatty liver disease: Noninvasive methods of diagnosing hepatic steatosis.

Authors:  Rasha AlShaalan; Murad Aljiffry; Said Al-Busafi; Peter Metrakos; Mazen Hassanain
Journal:  Saudi J Gastroenterol       Date:  2015 Mar-Apr       Impact factor: 2.485

7.  Diagnostic accuracy of acyl-ghrelin and it association with non-alcoholic fatty liver disease in type 2 diabetic patients.

Authors:  Galyna Mykhalchyshyn; Nazarii Kobyliak; Petro Bodnar
Journal:  J Diabetes Metab Disord       Date:  2015-05-19

8.  Association Between the Severity of Nocturnal Hypoxia in Obstructive Sleep Apnea and Non-Alcoholic Fatty Liver Damage.

Authors:  Erol Cakmak; Faysal Duksal; Engin Altinkaya; Fettah Acibucu; Omer Tamer Dogan; Ozlem Yonem; Abdulkerim Yilmaz
Journal:  Hepat Mon       Date:  2015-11-28       Impact factor: 0.660

Review 9.  Ultrasound imaging of the liver and bile ducts - expectations of a clinician.

Authors:  Krzysztof Skoczylas; Andrzej Pawełas
Journal:  J Ultrason       Date:  2015-09-30

Review 10.  Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification.

Authors:  Dong Ho Lee
Journal:  Clin Mol Hepatol       Date:  2017-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.